{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:57:12Z","timestamp":1788472632145,"version":"build-2803163510"},"reference-count":25,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ketamine has been used in anesthesia, pain management, and major depressive disorder. It has recently been studied in patients with post-traumatic stress disorder (PTSD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the impact of ketamine on PTSD symptomatology and depression scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a literature search of Medline 1960 to May 20, 2023, and found 6 randomized controlled trials that met our inclusion criteria. We extracted data on the Clinician-Administered PTSD (CAPS), PTSD Checklist (PCL), or Montgomery-Asberg Depression Rating (MADRS) scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The use of ketamine significantly reduced CAPS scores (n = 5, MD: \u221210.63 [95% CI \u221214.95 to \u22126.32]), PCL scores (n = 3, MD: \u22126.13 [95% CI \u22128.61 to \u22123.64]), and MADRS scores (n = 3, MD: \u22126.33 [95% CI \u22128.97 to \u22123.69]) at the maximal follow-up times versus control. Significant benefits were found at day 1 and weeks 1, 2, and 4 for CAPS and PCL scores as well as MADRS scores at day 1, week 1, and week 4 for ketamine versus control. The time to PTSD relapse was prolonged in the patients receiving ketamine versus control (n = 2, 15.74 days [95% CI 3.57 to 29.91 days]). More dry mouth (n = 2, OR 5.85 [95% CI 1.32 to 25.95]), dizziness (n = 2, OR 3.83 [95% CI 1.28 to 11.41]), and blurred vision (n = 2, OR 7.57 [1.00 to 57.10]) occurred with ketamine than control therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance:<\/jats:title>\n                    <jats:p>Ketamine modestly reduced PTSD and depression scores as early as 1 day of therapy, but the longevity of effect needs to be determined. Given similar magnitude of benefit with SSRIs and venlafaxine, ketamine would not supplant these traditional options for chronic use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231199666","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T08:57:05Z","timestamp":1696064225000},"page":"669-677","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["The Impact of Ketamine for Treatment of Post-Traumatic Stress Disorder: A Systematic Review With Meta-Analyses"],"prefix":"10.1177","volume":"58","author":[{"given":"Dakota J.","family":"Sicignano","sequence":"first","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Kurschner","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nissen","family":"Weisman","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Sedensky","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"},{"name":"Research Administration, Hartford Hospital, Hartford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9367-4893","authenticated-orcid":false,"given":"C. Michael","family":"White","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"},{"name":"Research Administration, Hartford Hospital, Hartford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"bibr1-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2012.02.009"},{"key":"bibr2-10600280231199666","unstructured":"Veterans Affairs and Department of Defense. VA\/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder. Version 4.0; 2023. Accessed August 14, 2023. https:\/\/www.healthquality.va.gov\/guidelines\/MH\/ptsd\/VA-DoD-CPG-PTSD-Full-CPG.pdf"},{"key":"bibr3-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000708"},{"key":"bibr4-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1995"},{"key":"bibr5-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231154125"},{"key":"bibr6-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001395"},{"key":"bibr7-10600280231199666","unstructured":"Anon. Ketamine therapy: how much does it cost and who is eligible? Psychedelic Spotlight, January 12, 2023. Accessed May 4, 2023. https:\/\/psychedelicspotlight.com\/ketamine-therapy-how-much-does-it-cost-who-is-eligible\/"},{"key":"bibr8-10600280231199666","unstructured":"Sagonowsky E. Cost watchdogs scold J&J for \u201coverpricing\u201d its new ketamine-like antidepressant. Fierce Pharma, May 10, 2019. Accessed May 4, 2023. https:\/\/www.fiercepharma.com\/pharma\/icer-takes-issue-johnson-johnson-s-spravato-price-questions-breadth-data#:~:text=Before%20rebates%20and%20discounts%2C%20Spravato,quality%2Dadjusted%20life%20year%20gained"},{"key":"bibr9-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X221116477"},{"key":"bibr10-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01327-5"},{"key":"bibr11-10600280231199666","unstructured":"Colle C. PTSD Assessment Instruments. American Psychological Association; 2017. Accessed August 14, 2023. https:\/\/www.apa.org\/ptsd-guideline\/assessment"},{"key":"bibr12-10600280231199666","unstructured":"National Center for PTSD. Impact of Event Scale\u2014PTSD Checklist for DSM-5 (PCL-5). Department of Veterans Affairs. Accessed August 17, 2023. https:\/\/www.ptsd.va.gov\/professional\/assessment\/adult-sr\/ptsd-checklist.asp"},{"key":"bibr13-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2009.05.003."},{"issue":"3","key":"bibr14-10600280231199666","first-page":"77","volume":"47","author":"Anon","year":"2017","journal-title":"Psychopharmacol Bull"},{"key":"bibr15-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.62.Pradhan"},{"key":"bibr16-10600280231199666","doi-asserted-by":"publisher","DOI":"10.4103\/2542-3932.211589"},{"key":"bibr17-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2018.03.006"},{"key":"bibr18-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1177\/2470547020981670"},{"key":"bibr19-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20050596"},{"key":"bibr20-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01266-9"},{"key":"bibr21-10600280231199666","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00650"},{"key":"bibr22-10600280231199666","first-page":"517","volume":"55","author":"Van der Kolk BA","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"bibr23-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1158"},{"key":"bibr24-10600280231199666","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4185"},{"key":"bibr25-10600280231199666","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05548-2"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231199666","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231199666","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231199666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:21Z","timestamp":1777374801000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231199666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/10600280231199666"],"URL":"https:\/\/doi.org\/10.1177\/10600280231199666","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]}}}